drugset / Trial / NCT04373941

Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

NCT04373941

RandomizedParallel-groupOpen-labelTreatment

Summary

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who did not undergo Kasai surgery). Subjects who participate in the trial will be followed for 2 years.

Timeline

Start
2023-09-01
Primary completion
2024-08-31
Completion
2025-10-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject filgrastim Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications